Pierre Giglio to Glioblastoma
This is a "connection" page, showing publications Pierre Giglio has written about Glioblastoma.
Connection Strength
1.964
-
Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report. Neuroradiol J. 2019 Oct; 32(5):317-327.
Score: 0.529
-
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023 01 01; 9(1):112-121.
Score: 0.168
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol. 2022 06 11; 15(1):80.
Score: 0.162
-
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol. 2022 Jan; 156(2):399-406.
Score: 0.157
-
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
Score: 0.144
-
Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 12; 82(6):945-952.
Score: 0.125
-
RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016 Jun; 37(6):7525-34.
Score: 0.103
-
Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015 Feb; 35(2):615-25.
Score: 0.097
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.095
-
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013 Aug; 114(1):43-50.
Score: 0.087
-
Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab Brain Dis. 2013 Sep; 28(3):355-66.
Score: 0.086
-
Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012 Jun; 37(6):1192-200.
Score: 0.079
-
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov; 12(11):1167-72.
Score: 0.071
-
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
Score: 0.060